XELPROS Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Xelpros, and when can generic versions of Xelpros launch?
Xelpros is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has nineteen patent family members in seventeen countries.
The generic ingredient in XELPROS is latanoprost. There are twenty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the latanoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xelpros
A generic version of XELPROS was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.
Summary for XELPROS
| International Patents: | 19 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 75 |
| Patent Applications: | 4,566 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for XELPROS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for XELPROS |
| What excipients (inactive ingredients) are in XELPROS? | XELPROS excipients list |
| DailyMed Link: | XELPROS at DailyMed |
Pharmacology for XELPROS
| Drug Class | Prostaglandin Analog |
Anatomical Therapeutic Chemical (ATC) Classes for XELPROS
US Patents and Regulatory Information for XELPROS
XELPROS is protected by two US patents.
Patents protecting XELPROS
Ophthalmic composition comprising a prostaglandin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Ophthalmic composition comprising a prostaglandin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | XELPROS | latanoprost | EMULSION;OPHTHALMIC | 206185-001 | Sep 12, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sun Pharm | XELPROS | latanoprost | EMULSION;OPHTHALMIC | 206185-001 | Sep 12, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XELPROS
See the table below for patents covering XELPROS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 2010004211 | COMPOSICION OFTALMICA QUE COMPRENDE UNA PROSTAGLANDINA. (OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN.) | ⤷ Try a Trial |
| Brazil | PI0818459 | ⤷ Try a Trial | |
| South Korea | 20100087107 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XELPROS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0364417 | 9690031-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST |
| 0364417 | 97C0128 | France | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718 |
| 3461484 | 21C1024 | France | ⤷ Try a Trial | PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
